168 related articles for article (PubMed ID: 29970536)
1. EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
Noh CK; Wang HJ; Kim CM; Kim J; Yoon SY; Lee GH; Cho HJ; Yang MJ; Kim SS; Hwang JC; Cho SW; Roh J; Kim YB; Kim SJ; Kim BW; Cheong JY
Anticancer Res; 2018 Jul; 38(7):4101-4109. PubMed ID: 29970536
[TBL] [Abstract][Full Text] [Related]
2. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
[TBL] [Abstract][Full Text] [Related]
3. Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma.
Dai XM; Huang T; Yang SL; Zheng XM; Chen GG; Zhang T
Dis Markers; 2017; 2017():8495326. PubMed ID: 28572700
[TBL] [Abstract][Full Text] [Related]
4. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma.
Lima LDP; Machado CJ; Rodrigues JBSR; Vasconcellos LS; Junior EP; Vidigal PVT; Resende V
Can J Gastroenterol Hepatol; 2018; 2018():5970852. PubMed ID: 30112355
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
7. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy.
Yamada S; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Takasu C; Ishikawa D; Shimada M
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S436-42. PubMed ID: 24566861
[TBL] [Abstract][Full Text] [Related]
8. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
9. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.
Miltiadous O; Sia D; Hoshida Y; Fiel MI; Harrington AN; Thung SN; Tan PS; Dong H; Revill K; Chang CY; Roayaie S; Byrne TJ; Mazzaferro V; Rakela J; Florman S; Schwartz M; Llovet JM
J Hepatol; 2015 Dec; 63(6):1368-77. PubMed ID: 26220754
[TBL] [Abstract][Full Text] [Related]
10. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.
Zeng Z; Ren J; O'Neil M; Zhao J; Bridges B; Cox J; Abdulkarim B; Schmitt TM; Kumer SC; Weinman SA
BMC Cancer; 2012 Dec; 12():584. PubMed ID: 23216644
[TBL] [Abstract][Full Text] [Related]
11. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
Chan AW; Tong JH; Chan SL; Lai PB; To KF
Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
[TBL] [Abstract][Full Text] [Related]
12. Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization.
Rhee H; Nahm JH; Kim H; Choi GH; Yoo JE; Lee HS; Koh MJ; Park YN
Mod Pathol; 2016 Sep; 29(9):1038-49. PubMed ID: 27312064
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
[TBL] [Abstract][Full Text] [Related]
14. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis.
Zhou L; Zhu Y
Int J Surg; 2018 Aug; 56():274-280. PubMed ID: 29936198
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma.
Choi GH; Kim GI; Yoo JE; Na DC; Han DH; Roh YH; Park YN; Choi JS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1444-52. PubMed ID: 25791790
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection.
Chen RX; Xia YH; Cui JF; Xue TC; Ye SL
J Gastroenterol Hepatol; 2010 Aug; 25(8):1435-42. PubMed ID: 20659235
[TBL] [Abstract][Full Text] [Related]
18. Perinodular ductular reaction/epithelial cell adhesion molecule loss in small hepatic nodules.
Zhang Q; Zhang CS; Xin Q; Ma Z; Liu GQ; Liu BB; Wang FM; Gao YT; Du Z
World J Gastroenterol; 2014 Aug; 20(31):10908-15. PubMed ID: 25152593
[TBL] [Abstract][Full Text] [Related]
19. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation.
Hwang HS; Yoo JE; Han DH; Choi JS; Lee JG; Joo DJ; Kim MS; Kim SI; Choi GH; Park YN
Gut Liver; 2022 May; 16(3):443-455. PubMed ID: 34737243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
